Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,868.46 +961.81 (+1.44%) CMC Crypto 200
1,371.12 +40.52 (+3.05%)
Ecolab Inc. (ECL)
After hours:
| Previous close | 243.66 |
| Open | 244.68 |
| Bid | 244.37 x 800 |
| Ask | 246.08 x 900 |
| Day's range | 243.44 - 246.86 |
| 52-week range | 156.72 - 248.60 |
| Volume | |
| Avg. volume | 1,052,853 |
| Market cap | 70.033B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | 45.33 |
| EPS (TTM) | 5.41 |
| Earnings date | 30 Jul 2024 |
| Forward dividend & yield | 2.28 (0.94%) |
| Ex-dividend date | 18 Jun 2024 |
| 1y target est | 249.71 |
ZacksCountdown to Ecolab (ECL) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of Ecolab (ECL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
ZacksFactors Setting the Tone for Ecolab's (ECL) Q2 Earnings
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
GlobeNewswireBioProcess360 Partners launch dedicated Life Sciences investment fund to grow emerging bioprocessing tools and technologies
Will connect innovators with investment, hands-on expertise and the leading biopharmaceutical manufacturers DELRAY BEACH, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- BioProcess360 Partners today announced the launch of a new investment fund to support businesses with the growth of emerging tools and technologies used in the bioprocessing of traditional mAbs and newer drug modalities. BioProcess360 Partners will support businesses through R&D and commercialization challenges by combining investment c
